A Meta-Analytic Review of Cognitive Functioning in Negative and Positive Symptoms of Schizophrenia by Forsythe, Tiffany
Abilene Christian University
Digital Commons @ ACU
Electronic Theses and Dissertations Electronic Theses and Dissertations
Spring 5-2019
A Meta-Analytic Review of Cognitive Functioning
in Negative and Positive Symptoms of
Schizophrenia
Tiffany Forsythe
txf16b@acu.edu
Follow this and additional works at: https://digitalcommons.acu.edu/etd
Part of the Clinical Psychology Commons, Mental Disorders Commons, Other Psychiatry and
Psychology Commons, and the Psychological Phenomena and Processes Commons
This is brought to you for free and open access by the Electronic Theses and Dissertations at Digital Commons @ ACU. It has been accepted for
inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ ACU.
Recommended Citation
Forsythe, Tiffany, "A Meta-Analytic Review of Cognitive Functioning in Negative and Positive Symptoms of Schizophrenia" (2019).
Digital Commons @ ACU, Electronic Theses and Dissertations. Paper 132.
  
 
ABSTRACT 
The purpose of the study was to conduct two meta-analytic reviews examining cognitive 
functioning and schizophrenia. The first review examined the literature comparing the 
cognitive functioning of schizophrenic patients to healthy controls. A second review 
examined the cognitive functioning within schizophrenic patients, examining the 
differences between individuals with primarily positive symptomatology and those with 
primarily negative symptomatology. The first meta-analysis included 19 studies which 
assessed 861 schizophrenic patients and 858 healthy volunteers overall. The second meta-
analysis included 10 studies comparing the cognitive functioning of 1,263 schizophrenics 
across positive and negative symptoms. Results of the first review indicated that healthy 
controls performed better than schizophrenics in all areas of neuropsychological 
functioning. Results of the second meta-analysis indicated that schizophrenics with 
primarily positive symptomatology performed better in all areas of functioning, with the 
exception of attention. 
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CHAPTER I 
A META-ANALYTIC REVIEW OF COGNITIVE FUNCTIONING IN NEGATIVE 
AND POSITIVE SYMPTOMS OF SCHIZOPHRENIA 
Epidemiology and Diagnostic Criteria of Schizophrenia 
Researchers have found that 1.1% of the world-wide population are diagnosed 
with schizophrenia (Schizophrenia and Related Disorders Alliance of America, 2018) and 
according to the World Health Organization, this number is about 21 million people, 
worldwide (World Health Organization, 2018). The literature on etiology is continually 
expanding and suggests a multifactorial etiology including genetic and environmental 
factors. Schizophrenia is categorized under psychotic disorders, and clinical symptoms 
include by delusions, hallucinations, disorganized thinking, disorganized motor behavior, 
blunted affect, avolition, anhedonia, alogia, and asociality (American Psychiatric 
Association, 2013). Individuals diagnosed with schizophrenia will vary widely in these 
symptoms due to its heterogeneity (American Psychological Association, 2013). 
Cognitive symptoms are also present in schizophrenia and include changes in memory, 
attention, and executive functioning (National Institute of Mental Health, 2016). 
Cognitive impairment is central in predicting functional outcome of those diagnosed with 
schizophrenia and predicting the prognosis one might face (Bowie & Harvey, 2006). 
Declining cognitive abilities can overlap and impact many areas of an individual’s life, 
such as vocational, social, and daily living skills, leading to increased disability reliance. 
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Schizophrenia has unfolded over the years as a neuropsychological disease, responding to 
neuroleptic medications and neuropharmacological research (Liberman & Corrigan, 
1992).  
 Genetic Factors and Biology 
 According to the National Alliance of Mental Illness, schizophrenia is linked to a 
genetic predisposition (National Alliance of Mental Illness, 1998). Multiple studies have 
found a high degree of heritability of schizophrenia (Gareeva & Khusnutdinova, 2018). 
Genetic research is emerging as a promising contribution to understanding schizophrenia 
development. Bassett, Chow, Weksburg, & Brzustowicz (2002) discussed the 
identification of 22q deletion syndrome (22qDS), multiple susceptibility genes, and new 
mutations. The mutation 22qDS is characterized by microdeletions in the “Q” arm of 
chromosome 2, which increases the risk for schizophrenia (Basset et al., 2002) as well as 
other neurodevelopmental brain disorders (Larsen, Dzafic, Siebner, & Garrido, 2018). 
The 22qDS mutation is characterized by abnormalities in sensory processing and 
cognition (Larsen et al., 2018). Studies that have examined this mutation have found that 
those individuals with 22qDS are at risk to develop psychosis, and over 25% will develop 
schizophrenia (Bassett et al., 2002; Murphy, Jones, & Owen, 1999). According to the 
Encyclopedia of the Human Genome, (Murphy, 2003) 22q11, better known as 
Velocardiofacial Syndrome, is the most significant risk factor for the development of 
schizophrenia. Statistically, the rate of 22q11.2 microdeletion is estimated at a rate of 1 
per 4,000 live births making it the most common microdeletion syndrome (Bassett et al., 
2002).  
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There is also increased evidence for another gene, DISC1, disrupted in 
schizophrenia 1 gene, associated with schizophrenia in Scottish and Finnish population 
(Ekelund et al., 2001; Millar et al., 2000; Prus, 2018). This gene codes for the DISC1 
protein, which mediates signaling events occurring within neurons and is involved in the 
development of neurons (Hayashi-Takagi et al., 2010; Hodgkinson et al., 2004; Mao et 
al., 2009; Prus, 2018). Hodgkinson et al. (2004) propose that haploinsufficiency is a 
possible precursor to DISC1 disruption, and Hayashi-Takagi et al. (2010) further posit 
disturbances in glutamatergic neurotransmission through DISC1 disruption and potential 
changes to dendritic spines.  
 Not only can genetic mutations affect risk of schizophrenia but alterations in 
epigenetic regulation of normal genes through DNA methylation have been reported in 
the brains of patients with psychosis (Chen et al., 2014). Methylation is the additive of a 
methyl group. DNA methylation reduces gene expression, and demethylation increases 
gene expression. These processes are being explored with regard to the etiology of 
schizophrenia (Grayson & Guidotti, 2013). Jaffe et al. (2016) examined changes in DNA 
methylation levels in relation to genetic sequence and developmental stage associated 
with clinical risk for schizophrenia (Jaffe et al., 2016).  
 Recent evidence also suggests that the cerebellum plays an important role in 
schizophrenia and other psychotic disorders, leading researchers to search the cerebellum 
for psychosis (Chen et al., 2014). To date, cerebellar function is associated with 
depression and mania (Konarski, McIntyre, Grupp, & Kennedy, 2005). Konarski et al. 
(2005) presented evidence that those with schizophrenia have modified cortico-cerebellar 
connectivity. Andreasen et al. (1996) and Wiser et al. (1998) reported the role of the 
 4 
 
cortico-cerebellar connectivity in monitoring and coordinating the fluid execution of 
mental activity geared toward normal cognitive functioning.  Disruption of these 
pathways could lead to the disordered cognition and clinical symptoms of schizophrenia. 
 The prefrontal cortex (PFC) has played a more famously recognized role of 
schizophrenia symptomatology. The PFC is responsible for language, speech, and 
executive functions, which are disrupted in schizophrenia (Andreasen, Paradiso, & 
O’Leary, 1998). The PFC also shows extensive interconnections with other cortical and 
subcortical regions that are affected by schizophrenia (Andreasen, Paradiso, O’Leary, 
1998). Other related areas being researched include the thalamus and hippocampus 
(Andreasen, Paradiso, & O’Leary, 1998; Pakkenberg, 1990; Stevens, 1982; Vukadinovic, 
2014). 
 Historically, the first etiologic hypothesis for schizophrenia was the dopamine 
hypothesis (Prus, 2018). The dopamine hypothesis explains positive symptoms of 
schizophrenia as due to increased dopamine release in the mesolimbic system (Meltzer & 
Stahl, 1976; Prus, 2018) This hypothesis remains influential in schizophrenia (Howes & 
Kapur, 2009; Prus, 2018). Glutamate is another neurotransmitter that has been found to 
play a role in the etiology of schizophrenia, with decreased in glutamate release 
throughout the cerebral cortex and limbic system of schizophrenia patients (Paz, Tardito, 
Atzori, & Tseng, 2008; Prus, 2018; 2008; Sesack, Carr, Omelchecnko, 2006).  
 Overall, the neurological understanding of the development of schizophrenia is 
complex and intricate, including genetic abnormalities, reduced volume within brain 
structures, and unusual or atypical connectivity among brain structures (Lewis & 
Lieberman, 2000; Prus, 2018, Ross, Margolis, Reading, Pletnikov, & Coyle, 2006). 
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Environmental Factors  
Environmental risk factors for schizophrenia include elements of both the prenatal 
uterine environment and the external environment in which the individual continues to 
develop following birth. Vulnerability to schizophrenia can be increased by disruptions in 
brain development as a result of prenatal and perinatal complications, maternal substance 
misuse, and early life stressors (Howes et al., 2003). The uterine environment is vital to 
development and decreased folate levels during pregnancy have been linked to 
schizophrenia risk (Opler et al., 2013). Many schizophrenia studies have reported a 
linkage with season of birth and schizophrenia (Demler, 2011; Torrey, Rawlings, Ennis, 
Merrill, & Flores, 1996), and other studies have explored the interaction of folate levels 
and birth season (Muntjewerff, Ophoff, Buizer-Voskamp, Strengman, & Heijer, 2011). 
Late winter and early spring births are correlated to increased risk of schizophrenia. 
Interestingly, summer births are associated with predominantly negative symptoms of 
schizophrenia (American Psychological Association, 2013). 
More recently, research reports that paternal age may be a link to schizophrenic 
predisposition, and this may be increasingly important as couples are starting to build 
their families later in life (American Psychological Association, 2013; Bassett, Chow, 
Weksberg, & Brzustowicz, 2002). Studies suggest that paternal ages 40 years old and 
above increase the risk for schizophrenia in their offspring (Byrne, Agerbo, Ewald, 
Eaton, & Mortensen, 2003; Malaspina, Harlap, & Fenning, 2001).  
Socioeconomic factors have been considered due to exposure to pollution, stress, 
and increased risk behaviors (Opler, Charap, Greig, Stein, Polito, & Malaspina, 2013). 
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By impacting neural and cognitive development, socioeconomic factors can increase an 
individual’s susceptibility to psychosis (Opler et al., 2013; Spauwen, Krabbendam, Lieb, 
Wittchen, & Van Os, 2004). 
Positive and Negative Symptomatology 
 As early as 1861, Russell Reynolds introduced the distinction between positive 
and negative neurological symptoms as excess or deficit of vital properties (Pearce, 
2004). Reynolds, along with Hughlings Jackson, can be credited with the application of 
positive and negative symptoms to psychiatry (Pearce, 2004). By 1970, the terms 
negative and positive symptoms emerged as diagnostic terminology in schizophrenia 
(Jablensky, 2010). To date, according to The National Institute of Mental Health (2016), 
schizophrenic symptoms can be classified into three categories: positive, negative, and 
cognitive. Schizophrenia symptoms make reliable sub-phenotypes due to the genetic 
basis for differences in their clinical presentations (Arnedo et al., 2015). These sub-
phenotypes also have characteristic heritability of symptoms (Kendler et al., 1993). The 
availability of valid and reliable measures of negative and positive symptoms such as 
Positive and Negative Syndrome Scale (PANSS), Scale for Assessment of Positive 
Symptoms (SAPS), and Scale for Assessment of Negative Symptoms (SANS) (Kay, 
Flazbein, & Opler, 1987) contribute to the conversation of sub-phenotypes.   
 Epidemiology and diagnosis. Positive symptoms in schizophrenia include 
symptoms in excess of normal and healthy functioning. Positive symptoms include 
hallucinations, delusions, thought disorder, and movement disorder (National Institute of 
Mental Health, 2016). Negative symptoms in schizophrenia include absences or 
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disruption to normal emotions and behaviors, such as a flat affect, anhedonia, alogia, and 
avolition (National Institute of Mental Health, 2016).  
Fenton and McGlashan (1991) found that individuals with primarily negative 
symptoms experience a more severe and progressive course leading to permanent 
disability, whereas individuals with fewer negative symptoms experience better 
functioning and better a prognosis. Individuals with positive symptomatology were at 
higher risk for hospitalization (Fenton & McGlashan, 1991). Positive and negative 
symptomatology can be measured by scales such as the PANSS (positive and negative 
syndrome scale; Kay, Fiszbein, & Opler, 1987), SANS (scale for the assessment of 
negative symptoms; Andreasen, 1989), and SAPS (scale for the assessment of positive 
symptoms; Andreasen, 1984). 
 Etiology of positive and negative symptoms. Cognitive dysmetria is a theory 
that seeks to explain positive and negative symptomatology in schizophrenia (Prus, 
2018). Cognitive dysmetria is characterized by abnormalities with receiving and 
processing information and has been linked to individuals experiencing hallucinations, 
forming delusions, disorganized speech, impaired attention, and unusual responses to 
emotions, all characteristic of schizophrenia (Prus, 2018). Negative symptoms of 
schizophrenia have also been linked to genes in the folate metabolic pathway (Roffman et 
al., 2011). Folate is an important vitamin involved in intracellular methylation, and 
alteration in folate metabolism can affect normal brain development and function 
(Frankenburg, 2007). Dopamine also plays a significant role in negative and positive 
symptomatology in the mesolimbic pathway (Xavier & Vorderstrasse, 2017) . Abi-
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Dargham (2004) concluded that dopamine depletion in the prefrontal cortex produce 
cognitive impairment and negative symptomatology.   
 Positive symptoms of schizophrenia have been linked to separate genes such as 
MDR1 (multidrug resistance 1), with polymorphisms of this gene being associated with 
hallucinations and bizarre behavior quintessential of positive symptomatology (Tovilla-
Za’rate et al., 2014). Excessive dopaminergic action is another contribution to positive 
symptoms in schizophrenia which has been a long-standing hypothesis in schizophrenia. 
Anissa Abi-Dargham reported that sustained exposure to D2 receptor agonists induced 
schizophrenia-like positive symptoms (Abi-Dargham, 2004).  Neurotransmitters 
associated with positive symptoms include dopamine and serotonin (Abi-Dargham, 
2004). Abi-Dargham (2004) explains how dopamine excesses and deficits can 
simultaneously produce positive and negative symptoms, respectively. He reports that 
this is due to the excess of dopamine in subcortical structures such as the nucleus 
accumbens and a deficit of dopamine in the cerebral cortex (Abi-Dargham, 2004). The 
neurotransmitter systems producing positive and negative symptoms include dopamine, 
serotonin, glutamate, and GABA. Another important neurochemical in schizophrenia is 
BDNF or brain- derived neurotrophic factor (Chen et al., 2014; Xavier & Vorderstrasse, 
2017), which helps maintain and form new neurons (Prus, 2018). More specifically, low 
levels of plasma BDNF are related to negative symptomatology (Chen et al., 2014; 
Xavier & Vorderstrasse, 2017). 
Neuropsychological Function in Schizophrenia 
 Multiple studies have found significant deficits associated with schizophrenia in 
attention, memory, processing speed, motor functioning, and executive functioning 
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(Martin, Mowry, Reutens, & Robinson, 2015; Schulze-Rauschenbach et al., 2015). 
Literature has found that cognitive impairment precedes the onset of the first psychotic 
episode (Muntean et al., 2018).  
 Negative symptomatology in schizophrenia is associated with a great decline in 
memory, verbal learning, nonverbal memory, verbal fluency, and processing speed 
(O’Leary et al., 2000). In terms of neuropsychological testing, subjects with negative 
symptomatology performed worse on IQ, Wisconsin Card Sorting Test, and The 
Newcombe Word Fluency (Addington, Addington, & Maticka-Tyndale, 1991).   
 Positive symptomatology in schizophrenia has not shown associations with 
cognitive impairment when compared to negative symptomatology. Research has shown 
that cognitive impairment is far more prominent in negative symptomatology (Addington 
et al., 1991) and improvement in positive symptoms is related to improvement of 
cognitive functioning (Addington et al., 1991).  
 Executive function. Individuals with schizophrenia have difficulty with 
executive function tasks such as planning, organizing, cognitive flexibility, using new 
information and problem solving. Cognitive deficits in tasks that measure executive 
functioning are experienced in a variety of disorders that affect prefrontal regions 
(Martin, Mowry, Reutens, & Robinson, 2015). 
 Processing speed. Cognitive functioning depends on uniform activity between 
brain regions, requiring proper speed and efficiency of information transfer which arises 
from white matter microstructure (Alloza et al., 2016; Bruce et al., 2017). Processing 
speed allows multiple cognitive processes to be available to the individual and is a piece 
of higher order cognition (Alloza et al., 2016; Kail & Salthouse, 1994). Accelerated 
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aging, which also impacts cerebral white matter, has also been linked to the 
schizophrenic brain (Alloza et al., 2016). 
 Attention. Attention is widely dispersed among neurocognitive functions and can 
encompass a wide range of tasks. This makes it difficult to isolate attention impairments 
in tasks from other impairments in the same tasks (Luck & Gold, 2008). Studies have 
shown different findings regarding increased and decreased activity in areas of the 
schizophrenic brain and largely attribute this to the fact that attention is a multi-faceted 
construct and that certain tasks can measure different areas of attention (Carter et al., 
2010).  
 Memory. Memory deficits seen in schizophrenia have been linked to disruptions 
to the hippocampus (Zuckerman Institute, 2017). This same team completed an animal 
study in which schizophrenic-like mice compared to healthy mice were studied for 
memory by their ability to navigate through an environment that changed (Zuckerman 
Institute, 2017). Another study indicated that pairing memory tasks with affective stimuli 
may increase the ability to recall in schizophrenic patients (Fairfield et al., 2016). 
Meta-Analysis 
A meta-analysis is a quantitative review of the literature that combines data from 
previous research studies, used to synthesize data. A meta-analysis is conducted by 
forming a hypothesis and running a search on articles in databases such as PsycINFO. 
Identifying articles that pertain to the hypothesis is vital and involves identifying studies 
that meet the specific inclusion criteria of the study. The main statistic used in a meta-
analytic review is the effect size. The effect size is a standardized measure of association 
(like the correlation coefficient) or difference between groups. Effect sizes for group 
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differences (like Cohen’s d or Glass’ delta) are typically computed by subtracting the 
mean of the two groups and dividing by a standard deviation. After effect sizes have been 
identified or calculated for each study, effect sizes are summed and averaged to compute 
the grand effect size, a single metric that quantitatively summaries the research literature.  
Present Study 
 Schizophrenia is a disabling disease that impacts the individual, the family, and 
the community. Multiple factors including genetics and environment lead to 
neuropsychological impairments throughout the course of schizophrenia. Clinicians have 
identified symptomatologic subtypes of schizophrenia, classified as negative and 
positive. Identifying the predominance of positive or negative symptom clusters can 
inform the prognosis for treatment compliance, disease progression, and treatment 
outcome. Research has found that individuals with schizophrenia have a marked 
impairment in neuropsychological functioning when compared to healthy controls and 
that progression of the disease aligns with progression of neuropsychological impairment 
(Herold, Schmid, Lasser, Seidl, & Schroder, 2017). Research has also found that those 
individuals with predominantly positive symptoms experience less severe 
neuropsychological impairment and a better response to treatment (Addington, 
Addington, & Maticka-Tyndale, 1991).  
 To date, research has found significant differences in neuropsychological 
functioning between schizophrenia and healthy controls. However, no quantitative review 
of the literature has been done. The first goal of the present study is to complete a 
quantitative review of the literature that has examined neurological functioning in 
schizophrenic individuals compared to a healthy control sample. It was predicted that the 
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review will indicate that schizophrenia is associated with reduced executive functioning, 
processing speed, attention, and memory.  
 Research has also indicated differences in neurological functioning between 
negative and positive subtypes of schizophrenia when compared to each other. Currently, 
however, there is no quantitative review of the literature looking at the relationship of 
symptomatology with neurological functioning.  Consequently, the second goal of the 
proposed study was to conduct a meta-analytic review comparing neurological 
functioning between negative and positive symptoms of schizophrenia.  It was predicted 
that individuals with negative symptomatology will show larger deficits in executive 
functioning, processing speed, attention, and memory.   
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CHAPTER II 
METHOD 
Neuropsychological Function: Normal Population vs Schizophrenia 
 A systematic search was conducted to identify studies that have compared 
neurological functioning in schizophrenia and healthy control samples. The literature 
search used databases such as psycINFO. The keyword combination used in the search 
included combinations of the following: “IQ” (or “Intelligence”), “neurological 
functioning,” “cognitive performance,” “cognition,” “neurocognitive,” 
“neuropsychological,” “schizophrenia,” and “psychosis.” The studies were carefully 
examined and evaluated to determine whether they fulfilled the inclusion criteria and 
provided descriptive statistics and standard deviations. Additional studies were obtained 
through cross-references. 
Inclusion criteria consisted of the following: 1) Include studies that assessed a 
sample of persons diagnosed with schizophrenia following the DSM or ICD, 2) 
Comparison of schizophrenic patients with a healthy control group having no history and 
familial history of psychosis, 3) Provide quantitative measures of cognitive functioning, 
and 4) Be published in English in scientific peer-review journals. The effect size was 
calculated by subtracting group means on cognitive measures and dividing by the pooled 
standard deviation. The pooled standard deviation was calculated by adding the standard 
deviations together from both groups and then dividing by two. Grand effect sizes 
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involved totaling and averaging effect sizes across studies, cognitive function, and 
assessment instruments. 
Based on the above inclusion criteria, 19 studies were included in the meta-
analysis. Overall, across these 19 studies, 861 schizophrenic patients were assessed and 
858 healthy controls, who were mostly designated as community volunteers (Table 1). 
Neuropsychological Function: Positive vs. Negative Schizophrenia  
 A second systematic search was conducted to identify studies that examined 
neurological functioning across positive versus negative symptomatology in 
schizophrenia. The keyword combination used in the search included the following: 
“negative versus positive symptomatology,” “symptomatology in schizophrenia,” and 
“neuropsychological,” “cognitive performance,” or “performance differences”. Studies 
were carefully examined and evaluated to determine whether they fulfilled the inclusion 
criteria and provided descriptive statistics and standard deviations. Additional studies 
were obtained through cross-references.  
Inclusion criteria included the following: 1) A sample of schizophrenic patients 
assessed for negative and positive symptomatology, 2) Provided quantitative measures of 
cognitive testing or subtests, and 3) Be published in English in scientific peer-review 
journals.  Effect sizes were again calculated by subtracting group means and dividing by 
the pooled standard deviation.   
For this second meta-analysis, 10 studies were identified that met inclusion 
criteria. Across these 10 studies 1,263 patients were included in the final review (Table 
4). 
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CHAPTER III 
RESULTS 
Meta-Analysis Comparing Neuropsychological Functioning Between Schizophrenia 
and Healthy Controls 
 It will be recalled that the purpose of the first meta-analysis was to look at the 
comparison of neuropsychological functioning between schizophrenic patients and 
healthy controls. Based upon the inclusion criteria, 19 studies were identified comparing 
861 schizophrenic patients with 858 healthy controls. The schizophrenic sample 
consisted of a fairly even split between inpatient and outpatient individuals, and most 
healthy controls were community volunteers. Individual effect sizes were computed for 
every neuropsychological measure and then averaged to create the grand effect sizes, 
giving an estimate of the total difference between controls and the schizophrenic group. 
The overall effect size for each study can be found in Table 1 along with the grand effect 
size.  
As can be seen in Table 1, in all instances but two, normal controls showed better 
neurological functioning. In two studies, schizophrenic patients outperformed healthy 
controls (Hager et al., 2015 and Krkovic et al., 2017). Overall, the grand effect size 
across the 19 studies was .79. According to Cohen’s interpretation, an effect size of .79 
falls in the large effect size range (Cohen, 1977). This effect size indicates that the 
average person in the healthy control group outperformed 78.52% of the schizophrenic 
group.i 
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 In addition to calculating the overall effect size for each study, effect sizes were 
also calculated for different domains of neuropsychological functioning. Table 2 presents 
effect sizes for neuropsychological functioning across the following domains: Executive 
functioning, attention, memory, and processing speed. The tests that were used across the 
studies that assessed executive functioning included: Wisconsin Card Sorting Test, Trails 
B, Digit Span total, and Stroop Word-Color. The tests that were used for processing 
speed included Trails A and the Conners’ Continuous Performance Test Hit Reaction 
Time. The test used for attention included the Digit Span Forward and Conners’ 
Continuous Performance Test detectability. The test used for memory included Digit 
Span Backward.  
As can be seen in Table 2, across all measures of executive functioning, 
processing speed, attention, and memory, healthy controls outperformed the 
schizophrenic group in all areas. The overall effect size for executive functioning was 
.83. This was the same effect size for processing speed. These effect sizes represent a 
large effect per Cohen, with healthy controls performing better than 79.67% of 
schizophrenics in the areas of executive functioning and processing speed. The overall 
effect size for attention was .51, resulting in a medium effect size per Cohen. When 
broken down into percentiles, the average healthy control outperformed 69.35% of the 
schizophrenic patients in measures of attention. Finally, the overall effect size of memory 
was .34, which falls into the medium effect size per Cohen. The average healthy control 
outperformed 63.31% of the schizophrenic patients on measures of memory.  
 An additional analysis computed effect sizes across assessment instruments. 
These effect sizes are presented in Table 3. As can be seen in Table 3, the 
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neuropsychological measures that were used consisted of Trails A, Trails B, Digit Span 
Forward, Digit Span Backward, Stroop Word-Color, Wisconsin Card Sorting Test, and 
The Conners’ Continuous Performance Test. Across all measurements of 
neuropsychological functioning, healthy controls outperformed schizophrenics. The 
lowest effect size was .30 for the Conners’ Continuous Performance Test Detectability, 
and the highest effect size was 1.14 for the Stroop Word-Color Test.  
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Table 1 
Studies in Meta-Analysis, Population, and Overall Effect Sizes 
Study: Schizophrenia N Healthy Controls N d 
Breton et al. 2011 52 outpatients 53 hospital staff .89 
Egan et al. 2011 30 patients 30 volunteers .49 
Ekerholm et al. 2012 36 inpatients 46 community .80 
Galaverna et al. 2012 32 inpatients 32 community 1.60 
Gigaux et al. 2013 10 outpatients 10 community 1.04 
Gorissen et al. 2005 64 outpatients 44 community 1.37 
Hager et al. 2015 29 in and outpatient 27 community -.06 
Herold et al. 2018 80 inpatients 60 community .71 
Hughes et al. 2002 62 outpatients 25 volunteers .67 
Kalwa et al. 2012 
Krkovic et al. 2017 
34 outpatients 
35 in and outpatient 
30 community 
28 community 
1.30 
-.44 
Laurensen et al. 2015 19 outpatients 30 volunteers 1.25 
Lopez-Luengo et al. 2016 89 inpatients 74 community .71 
Martino et al. 2007 21 outpatients 15 community 1.02 
Matsui et al. 2007 35 inpatients 24 community 1.44 
Nestor et al. 2014 48 patients 52 volunteers .74 
Perianez et al. 2007 127 inpatients 223 volunteers .62 
Sanz et al. 2012 40 inpatients 40 community .11 
Stone et al. 1998 18 males 15 male community .70 
 N = 861 N = 858 Grand d = .79 
Note: Positive d indicates that the healthy controls outperformed the schizophrenic 
sample 
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Table 2 
Studies in Meta-Analysis, Neuropsychological Functioning, and Overall Effect Sizes 
Study: Executive 
Functioning 
Attention Processing 
Speed 
Memory 
Breton et al. 2011 .86    
Egan et al. 2011 .21 .77   
Ekerholm et al. 2012 .78 .80 .85  
Galaverna et al. 2012   1.60   
Gigaux et al. 2013 1.09  .93  
Gorissen et al. 2005 1.37  1.38  
Hager et al. 2015  .15  -.21 
Herold et al. 2018 1.32 .28 .76 .49 
Hughes et al. 2002 .70 .51 .73  
Kalwa et al. 2012 
Krkovic et al. 2017 
1.26 
-.98 
.38 1.41 
-.71 
Laurensen et al. 2015 1.13  1.50  
Lopez-Luengo. 2016  .20 1.21  
Martino et al. 2007 1.02    
Matsui, 2007 1.44    
Nestor et al. 2014 .74    
Perianez et al. 2007 .63  .61  
Sanz et al. 2012  -.28 .49  
Stone et al. 1998   .65  .75 
Grand d:  .83 .51 .83 .34 
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Table 3 
 
Studies in Meta-Analysis, Neuropsychological Tests, and Overall Effect Sizes 
 
Study: STROOP TMT  
A 
TMT  
B 
DS 
F 
DS
B 
WCST 
CC 
CPT  
D 
CPT  
HRT 
Breton et al. 2011 1.05     .72   
Egan et al. 2011      .21 .77  
Ekerholm et al. 2012  .85 1.02   .54   
Galaverna et al. 2012    1.60     
Gigaux et al. 2013 .81 .93 1.37      
Gorissen et al, 2005 1.45 1.38 1.66      
Hager et al. 2015    .15 -.21    
Herold, 2018  .76 1.32 .28 .49    
Hughes et al. 2002  .80 .82   .58 .51 .66 
Kalwa et al. 2012 
Krkovic et al. 2017 
 1.41 
-.71 
1.58 
-.98 
.38  1.60  
Laurensen et al. 2015 1.23 1.50 1.03      
Lopez-Luengo, 2016       .20 1.21 
Martino et al. 2007      1.02   
Matsui, 2007    1.44     
Nestor et al. 2014      .74   
Perianez et al. 2007  .61 .63      
Sanz et al. 2012       -.28 .49 
Stone et al. 1998    .65 .75    
Grand d: 1.14 .84 .94 .75 .34 .77 .30 .79 
Note: STROOP = Stroop Test, TMT A and B = Trail Making Test A and B, DS F and B 
= Digit Span Forward and Backward, WCSTCC = Wisconsin Card Sorting Categories 
Completed, CPT D and HRT = Conners’ Continuous Performance Test Detectability and 
Hit Reaction Time  
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Meta-Analysis Comparing Negative and Positive Symptomatology of Neurological 
Functioning 
 A second purpose of this study was to look at the impact of positive and negative 
symptomatology upon neuropsychological functioning. Literature suggests that 
predominantly negative symptomatology is more associated with dysfunction than those 
experiencing predominantly positive symptomatology (Sarkar, Hillner, & Velligan, 
2015). Based on inclusion criteria, 10 studies were identified (Table 4). The 10 studies 
were comprised of 1,263 patients diagnosed with schizophrenia and consisted of inpatient 
and outpatient individuals. Most of the studies utilized the PANSS, SAPS, and SANS to 
assess symptomatology.  
For the studies found in Table 4, effect sizes were computed for all neurological 
assessments comparing negative and positive symptomatology groups and then averaged 
to create the overall effect size for that study. These effect sizes were then summed and 
averaged to compute the grand effect size. As can be seen in Table 4, across all studies, 
with two exception, Cascella et al. (2008) and Zakzanis (1998), predominantly positive 
symptomatology schizophrenics performed better than predominantly negative. The 
overall effect size was .51. The lowest effect size observed was -.95 and the highest 
observed was 1.91. When interpreting the overall grand effect size of .51, Cohen defines 
this as a medium effect size. Overall, this indicates that the average schizophrenic patient 
with positive symptomatology performed better than 69.35% of the schizophrenics with 
negative symptomatology.  
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Table 4  
 
Studies in Meta-Analysis, Population, and Overall Effect Sizes  
 
Study Sample N Negative/Positive 
Assessment 
d 
Bird, 1990 Outpatient 20 SANS/SAPS .26 
Brazo et al. 2002 Outpatient 26 SDS/PANSS .65 
Cascella et al. 2008 Inpatient/Outpatient 105 SANS/SAPS -.06 
Fervaha et al. 2016 Outpatient 657 PANSS .29 
Jonsdottir, 1992 Inpatient/Outpatient 20 SAPS/SANS .18 
Mattson et al. 1997 
Murray, 1990 
Inpatient 
Inpatient 
40 
32 
PANSS 
SANS/SAPS 
1.91 
.71 
Polgar et al. 2010 Inpatient 275 PANSS .77 
Singh et al. 1999 Outpatient 50 SANS/SAP 1.32 
Zakzanis, 1998 Inpatient/Outpatient 38 BPRS -.95 
  N = 1,263   Grand d = .51 
Note: SANS= Scale for the Assessment of Negative Symptoms SAPS= Scale for the 
Assessment of Positive Symptoms PANSS= The Positive and Negative Syndrome Scale 
BPRS= The Brief Psychiatric Rating Scale  
 
  
As with the first meta-analysis, effect sizes were also computed for each cognitive 
function. These effect sizes can be found in Table 5. The same measures went into the 
same categories of neuropsychological functioning. The results were very widespread.  
One negative effect size was observed with attention (d = -.12). This score indicates that 
schizophrenics with negative symptomatology performed better than schizophrenics with 
positive symptomatology, though this effect was small. The largest effect size was 
observed for memory (d = 1.15), indicating that schizophrenics with positive 
symptomatology performed on average over one standard deviation better than 
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schizophrenics with negative symptomatology. The overall effect size for executive 
functioning was .54, indicating that schizophrenics with positive symptomatology 
performed on average a half standard deviation better than the average schizophrenic 
patient with negative symptomatology. Lastly, the overall effect size for processing speed 
was observed to be .25, a small effect size, indicated that the average patient with positive 
symptomatology performed better than 59.99&%  patients with negative 
symptomatology.  
 
Table 5 
 
Studies in Meta-Analysis, Neuropsychological Functioning, and Overall Effect Sizes 
 
Study Executive 
Functioning 
Attention Processing 
Speed 
Memory 
Bird,1990 .58 -.26 .59 .66 
Brazo et al. 2002 .65    
Cascella et al. 2008 -.13  -.03  
Fervaha et al. 2016 .29    
Jonsdottir, 1991 
Mattson et al. 1997 
Murray, 1990 
.31 
2.66 
.68 
-.24 
 
.65 
.50 
.40 
1.01 
.00 
.52 
Polgar et al. 2010 .77    
Singh, 1999  -.77  3.41 
Zakzanis, 1998 -.95  -.97  
Grand d: .54 -.12 .25 1.15 
 
Effect sizes were also calculated for each cognitive assessment instrument. These 
effect sizes can be found in Table 6. The measures included were the WCST, Stroop, DS, 
TMT, and CPT. Across all measures, except two (DSF, CPT d’), patients with positive 
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symptomatology performed better. Overall, the effect size for the Stroop was observed to 
be .56, indicating that the positive symptomatology group outperformed the negative 
symptomology group on this assessment by over a half standard deviation. Following 
Cohen’s interpretation, this would be a medium effect size. The overall effect size for 
Trails A was observed to be .22. According to Cohen (1988), this is a small effect size. 
The overall effect size for Trails B was observed to be .87, a large effect. The overall 
effect size for Digit Span Forward (DSF) was observed to be -.16, indicating that positive 
symptomatology group performed worse than negative symptomology group on this 
measure of attention. The effect size for Digit Span Backward was 1.15, a large effect. 
The overall effect size for Wisconsin Card Sorting Test was .29, a medium effect 
indicating that the average participant with positive symptomatology performed better 
than 61.41% of those in the negative symptomatology group. The effect size for the 
Conners’ Continuous Performance Test Detectability was observed to be negative (d = -
.14), indicating that those in the negative symptomatology group performed better on the 
CPT d’ than the positive symptomatology group. The overall effect size for Continuous 
Performance Test Hit Reaction Time was .18, which is a small effect size per Cohen. 
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Table 6 
 
Studies in Meta-Analysis, Neuropsychological Testing, and Overall Effect Sizes 
 
Study: STROOP TMT 
A 
TMT 
B 
DSF DSB WCST
CC 
CPT 
D 
CPT 
HRT 
Bird, 1990  .59 .58 -.24 .66  -.28  
Brazo et al. 2002 .56     .73   
Cascella et al. 2008  -.23 -.16   -.10 .00 .18 
Fervaha et al. 2016      .29   
Jonsdottir, 1991 
Mattson et al. 1997 
Murray, 1990 
 .50 
.40 
1.01 
.43 
4.77 
.70 
-.24 
 
.65 
.00 
 
.52 
.19 
.55 
.65 
 
Polgar et al. 2010      .77   
Singh, 1999    -.77 3.41    
Zakzanis, 1998  -.97 -1.11   -.78   
Grand d: .56 .22 .87 -.16 1.15 .29 -.14 .18 
Note: STROOP = Stroop Test, TMT A= Trail Making Test A, TMT B= Trail Making 
Test B, DSF= Digit Span Forward, DSB= Digit Span Backward, WCSTCC= Wisconsin 
Card Sort; Categories Completed, CPD D = Conners’ Performance Test Detectability, 
CPT HRT= Conners’ Performance Test Hit Reaction Time 
 
Meta-Analysis Comparing Error Rates Between Schizophrenic Patients and 
Healthy Controls 
A final, exploratory analysis was made of the error rates during the 
neurocognitive testing of schizophrenic patients and healthy controls. Using the studies 
from Table 1, nine studies were identified that provided error rates for the Wisconsin 
Card Sorting Test and the Conners’ Continuous Performance Test. Effect sizes were 
calculated for Wisconsin Card Sorting Test for the errors made in perseverations, or 
repeating the prior rule despite clinician instructions. In addition, effect sizes were also 
 26 
 
computed for the number of incorrect responses on the Wisconsin Card Sorting Test that 
did not involve perseverations. Effect sizes were also calculated for omission errors on 
the CPT, the number of missed targets. Such errors indicate an individual was not 
responding to target stimuli, due to factors such as inattentiveness or a difficulty with 
focusing. Effect sizes were also calculated for commission errors on the CPT, which are 
incorrect responses to non-targets -- errors that can indicate inattention or impulsivity.  
Effect sizes for errors on cognitive tests between schizophrenic patients and 
normal controls are found in Table 7. Positive effect sizes indicate that healthy controls 
performed better (fewer errors) than schizophrenic patients. Across the studies, all effect 
sizes, except one, were positive, indicating that healthy controls had fewer errors.  
 
Table 7 
Studies Comparing Schizophrenics with Non-Patients, Errors and Overall Effect Sizes.  
Study WCST PE WCST NONPE CPT OM CPT COM 
Breton et al. 2011 .89 .61   
Egan et al. 2011 
Ekerholm et al. 2012 
.30 
.72 
-.05  
Hughes et al. 2002 .36  .69 .31 
Kalwa et al. 2012 1.34 1.93   
Lopez-Luengo, 2016   .93 .32 
Martino et al. 2007 1.05    
Nestor et al. 2014 .76 .30   
Sanz et al. 2012   1.20 .61 
Grand d: .77 .70 .94 .41 
Note: WCSTPE: Wisconsin Card Sorting, Perseverative Errors; WCSTNON, Wisconsin 
Card Sorting, Non-Perseverative Errors; CPTOM, Conners’ Continuous Performance 
Test, Omissions; CPTCOM, Conners’ Continuous Performance Test, Commissions 
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CHAPTER IV 
DISCUSSION 
 Schizophrenia effects more than 21 million people worldwide (World Health 
Organization, 2019) and continues to elude clinicians and researchers for a cure. 
Schizophrenia can be considered a brain disease with a chronic course and stable 
neurocognitive deficits (National Institute of Mental Health, 2016). Studies over the years 
have examined the relationship between schizophrenia and healthy controls on 
neurological functioning, and the goal of this meta-analysis was to contribute to that 
literature. Overall, 19 studies were identified that met inclusion criteria comparing a 
schizophrenic sample and healthy controls on some measure of neurological functioning. 
Across these studies, a total of 861 schizophrenia patients and 858 healthy controls were 
included. The overall effect size was .79, indicating that the average healthy control 
performed better than 78.52% of the schizophrenic patients. When broken down by 
neurological function, the greatest deficits were observed in the areas of processing speed 
and executive functioning. Overall, the meta-analysis was consistent with the findings 
that there are persistent neurological deficits associated with schizophrenia.   
 The second goal of the study was to conduct a meta-analysis looking at positive 
and negative symptomatology and neuropsychological functioning. For generations, 
clinicians and researchers have noted the complex presentation of schizophrenia 
symptoms. Schizophrenic patients presenting with negative symptoms display symptoms 
such as: blunt/flat affect, anhedonia, alogia, and avolition (National Institute of Mental 
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Health, 2016). Positive symptoms, by contrast, involve hallucinations and delusions 
(National Institute of Mental Health, 2016). Clinicians and researchers have noted a more 
disabling course for the disorder when negative symptoms are the primary presentation 
(Rabinowitz, 2012). Thus, a goal of this study was to look at the cognitive functioning of 
positive and negative schizophrenia. Based upon the inclusion criteria, 10 studies were 
identified involving 1,263 patients. Overall, the effect size between the symptom types 
calculated to .51, indicating that positive symptomatology performed better than 69.35% 
of the schizophrenics with primary negative symptoms with the most profound 
neuropsychological functioning deficit being memory.  
Implications 
Clinical Implications  
 From the time of diagnosis, the course of schizophrenia has deleterious effects on 
the individual, the family, and the community (Miller, 1996). Managing symptoms within 
the day-to-day function can be very difficult for those struggling with disease. When 
considering treatment of schizophrenia, it is in the best interest of the individual to have 
family support. Family therapy may be of benefit to both the patient and the support 
system (Dixon & Lehman, 1995; Jewell, Downing, & McFarlane, 2009). In light of the 
current review, beyond the need for psychopharmacological intervention cognitive 
remediation and other forms of skills-based therapies may be helpful for the individual 
(Lopez-Luengo et al., 2016; Sanz et al., 2012). Many researchers have noticed a better 
outcome and improved cognitive functioning with early diagnosis and intervention, such 
as psychopharmacology, cognitive remediation, psychotherapy, occupational therapy, 
and ongoing case management services (Herold et al., 2019; Hughes et al., 2003).  
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 Treatment compliance has been a long-standing concern and challenge for some 
individuals with schizophrenia (Fenton et al., 1997). Mental illness stigma, insight, 
substance use, medication side effects and lack of support, for example, can contribute to 
treatment non-compliance for those struggling with the diagnosis (Fenton et al., 1997). 
This can also raise clinical implications for neurocognitive functioning and treatment 
noncompliance. Cognitive functioning should be considered as early as diagnosis, and the 
discussion of selecting a caretaker or adult protective agency to assist when symptoms 
may impair adequate treatment could be a viable resource to treatment planning and 
compliance.  
 Currently, the Diagnostic and Statistical Manual of Mental Disorder (DSM), 5th 
edition (American Psychiatric Association, 2013) places cognitive impairment related to 
schizophrenia in the ‘Associated Features’ section, and states that cognitive impairment is 
linked to vocational or functional impairment (American Psychological Association, 
2013). In light of the current review, it may be beneficial to add the cognitive criteria to 
the diagnostic section in the DSM. In addition, based upon the present research, these 
cognitive criteria should be evaluated quantitatively (e.g., neuropsychological tests) 
rather than qualitatively (i.e., clinical impression).  
Lastly, antipsychotic medication should be considered. A majority of 
schizophrenic patients are prescribed second generation medications, with some 
individuals requiring first-generation medications (treatment resistance schizophrenia; 
TRS). It is important to understand the role that antipsychotics may have on cognitive 
deficits and if the side effects may worsen the deficits. Literature indicates that cognitive 
deficits are present in drug-naïve schizophrenic patients (Fatourous-Bergman et al., 2014; 
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Zhang et al., 2013), indicating that cognitive deficits are present in early stages of 
schizophrenia and continue with the progression of the disease.  
 Further, treatment of negative symptomatology can be more difficult for 
clinicians compared to positive symptoms (Ellenbroek & Cools, 2000; Sarkar, Hillner, & 
Velligan, 2015). Sensory gating deficits in schizophrenia expressed as difficulty tuning 
out irrelevant stimuli thus posing a challenge to maintaining attention (Freedman et al., 
1987; Judd et al., 1992; Lijffijt et al., 2009). Nicotine improves sensory gating in 
schizophrenia, and schizophrenic patients are at high-risk for smoking (Featherstone & 
Siegel, 2015). Examining the role of nicotine and the improvement of sensory gating 
could lead to treatments for improving cognitive functions without creating additional 
problems with the medication effects (Hoffer et al., 1957; Levin & Rezvani, 2002). 
Specifically, some medications have interactive effects when used with nicotine, 
however, studies have shown that smoking can alleviate some side effects of anti-
psychotics (Matthews, Wilson, & Mitchell, 2011). The impact, however, is that smoking 
impacts the metabolism of medications (Lyon, 1999; Ziedonis et al., 2006).  
Neuropsychological Implications 
 Neuropsychological advancements have had a great impact on uncovering the 
cognitive abilities of individuals across a variety of diagnoses. The biggest implication of 
the neuropsychological assessment’s role when testing cognitive functioning for specific 
diagnoses is the wide range of testing available and the need for a standardized 
measurement that allows for more concise data and interpretation. During the course of 
the study, it was difficult to pool data on several studies due to varying scores, 
procedures, and modifications being used. Studies ranged in interpretation procedures 
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with some studies using the scores set forth by the manuals and others using alternative 
scoring.  
 Neuropsychological testing provides substantial information for research in the 
schizophrenic population, and pairing this data with neuroimaging can improve the data 
being used for treatment and research. These findings could assist with determining the 
prognosis at a more discrete level, potentially from the prodromal phase throughout the 
duration of the disease. Literature supports that cognitive functioning may be useful as a 
vulnerability marker (Cornblatt, 2002; Davidson et al., 1999; Reichenberg, 2010). This 
proves the need for continued research on neuropsychological measures and 
schizophrenia from the early stages (prodromal) and into the depths of the disease, into 
the lifespan.  
Conclusion 
 In conclusion, this study gives evidence that schizophrenic patients experience 
distinct and significant cognitive decline. In addition, negative symptomatology was 
associated with greater cognitive impairment. Consequently, the assessment of positive, 
negative, and cognitive symptoms when diagnosing and treating schizophrenia must 
become routine in clinical practice. Regarding treatment recommendations based upon 
these findings, the implementation of skill-oriented therapies along with family 
involvement may lead to more successful treatments.  
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